Literature DB >> 24362454

Vertebral fractures affect functional status in postmenopausal rheumatoid arthritis patients.

Yasunori Omata1, Futoshi Hagiwara, Jinju Nishino, Ko Matsudaira, Yuho Kadono, Takuo Juji, Toshihito Mori, Hisanori Nakayama, Yuichi Nagase, Jun Hirose, Tetsuro Yasui, Takumi Matsumoto, Toshihiro Matsui, Shigeto Tohma, Sakae Tanaka.   

Abstract

Functional disability is a major concern in patients with rheumatoid arthritis (RA). This retrospective study investigated the risk factors for vertebral fractures (VFs) in postmenopausal RA patients and determined the impact of VFs on functional status. Data from a cohort of 200 postmenopausal RA patients in a single hospital registry were analyzed. Demographic and clinical data, imaging data from spine radiographs, and bone mineral density (BMD) data were collected from the patients at baseline and at the final visit (a mean of 2.9 years after the first visit). Risk factors for incident VFs and their impact on the modified health assessment questionnaire (mHAQ) were analyzed. Twenty-eight patients (14%) developed new VFs (NVFs). Logistic regression analysis adjusted for age, BMI, and disease duration revealed that daily dose of prednisolone, femoral neck BMD, use of active vitamin D3, and use of a bisphosphonate at baseline were factors associated with NVF, with odds ratios (95% confidence interval) of 1.27 (1.05-1.54), 0.94 (0.91-0.97), 0.34 (0.13-0.89), and 0.31 (0.12-0.82), respectively. Patients with NVF exhibited worse mHAQ scores and a greater increase in mHAQ scores from baseline compared with those without NVF. In conclusion, incident VFs were associated with reduced functional status in postmenopausal patients with RA. It is important to prevent VFs to maintain the functional status of RA patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24362454     DOI: 10.1007/s00774-013-0552-8

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  33 in total

1.  A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis.

Authors:  L Sinigaglia; A Nervetti; Q Mela; G Bianchi; A Del Puente; O Di Munno; B Frediani; F Cantatore; R Pellerito; S Bartolone; G La Montagna; S Adami
Journal:  J Rheumatol       Date:  2000-11       Impact factor: 4.666

2.  High prevalence of vertebral deformities in elderly patients with early rheumatoid arthritis.

Authors:  J Ursum; K Britsemmer; D van Schaardenburg; P T A Lips; B A C Dijkmans; W Lems
Journal:  Ann Rheum Dis       Date:  2009-09       Impact factor: 19.103

3.  Prevalence and risk factors of vertebral fractures in women with rheumatoid arthritis using vertebral fracture assessment.

Authors:  Abdellah El Maghraoui; Asmaa Rezqi; Aziza Mounach; Lahsen Achemlal; Ahmed Bezza; Imad Ghozlani
Journal:  Rheumatology (Oxford)       Date:  2010-03-31       Impact factor: 7.580

4.  The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis.

Authors:  P M Welsing; A M van Gestel; H L Swinkels; L A Kiemeney; P L van Riel
Journal:  Arthritis Rheum       Date:  2001-09

5.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

6.  Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women.

Authors:  Jonathan D Adachi; Silvano Adami; Stephen Gehlbach; Frederick A Anderson; Steven Boonen; Roland D Chapurlat; Juliet E Compston; Cyrus Cooper; Pierre Delmas; Adolfo Díez-Pérez; Susan L Greenspan; Frederick H Hooven; Andrea Z LaCroix; Robert Lindsay; J Coen Netelenbos; Olivia Wu; Johannes Pfeilschifter; Christian Roux; Kenneth G Saag; Philip N Sambrook; Stuart Silverman; Ethel S Siris; Grigor Nika; Nelson B Watts
Journal:  Mayo Clin Proc       Date:  2010-07-15       Impact factor: 7.616

7.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

8.  Association of bone mineral density and vertebral deformity in patients with rheumatoid arthritis.

Authors:  Bedriye Mermerci Başkan; Filiz Sivas; Ebru Alemdaroğlu; Semra Duran; Kürşat Ozoran
Journal:  Rheumatol Int       Date:  2007-02-08       Impact factor: 2.631

9.  Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

Authors:  S T Harris; N B Watts; R D Jackson; H K Genant; R D Wasnich; P Ross; P D Miller; A A Licata; C H Chesnut
Journal:  Am J Med       Date:  1993-12       Impact factor: 4.965

10.  Risk of vertebral fracture in women with rheumatoid arthritis.

Authors:  T D Spector; G M Hall; E V McCloskey; J A Kanis
Journal:  BMJ       Date:  1993-02-27
View more
  8 in total

Review 1.  RANKL as a therapeutic target of rheumatoid arthritis.

Authors:  Sakae Tanaka; Yoshiya Tanaka
Journal:  J Bone Miner Metab       Date:  2020-10-18       Impact factor: 2.626

2.  Dental treatments, tooth extractions, and osteonecrosis of the jaw in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study.

Authors:  Takefumi Furuya; Shigeru Maeda; Shigeki Momohara; Atsuo Taniguchi; Hisashi Yamanaka
Journal:  J Bone Miner Metab       Date:  2016-07-02       Impact factor: 2.626

3.  Occipitosacral Fusion for Multiple Vertebral Fractures with Kyphotic Deformity in a Patient with Mutilating Rheumatoid Arthritis: A Case Report.

Authors:  Tetsu Tanouchi; Takachika Shimizu; Masatake Ino; Naofumi Toda; Nodoka Manabe; Kanako Itoh; Keisuke Fueki
Journal:  Surg J (N Y)       Date:  2017-03-20

4.  Rheumatoid arthritis in tight disease control is no longer risk of bone mineral density loss.

Authors:  Ichiro Yoshii; Tatsumi Chijiwa; Naoya Sawada
Journal:  Osteoporos Sarcopenia       Date:  2020-06-04

5.  Factors associated with osteoporosis medication use in Japanese patients with rheumatoid arthritis: Results from the Institute of Rheumatology Rheumatoid Arthritis cohort study.

Authors:  Masanori Nakayama; Takefumi Furuya; Eisuke Inoue; Eiichi Tanaka; Katsunori Ikari; Atsuo Taniguchi; Hisahi Yamanaka; Masayoshi Harigai
Journal:  Osteoporos Sarcopenia       Date:  2020-05-20

6.  Effects of eldecalcitol and ibandronate on secondary osteoporosis and muscle wasting in rats with adjuvant-induced arthritis.

Authors:  Yuichi Ono; Naohisa Miyakoshi; Yuji Kasukawa; Hiroyuki Nagasawa; Hiroyuki Tsuchie; Manabu Akagawa; Itsuki Nagahata; Yusuke Yuasa; Chiaki Sato; Yoichi Shimada
Journal:  Osteoporos Sarcopenia       Date:  2018-12-01

7.  Incidence and predictors of fragility fracture in postmenopausal rheumatoid arthritis patients receiving oral bisphosphonates: a longitudinal observational study.

Authors:  Yuji Kishimoto; Yoshihiro Kato; Manami Uemura; Koji Kuranobu
Journal:  BMC Rheumatol       Date:  2022-02-28

8.  The influence of vertebral fracture on the functional disability of patients with rheumatoid arthritis.

Authors:  Soo-Kyung Cho; Joo-Hyun Lee; Minkyung Han; Seunghun Lee; Ji Young Kim; Jeong Ah Ryu; Yun Young Choi; Sang-Cheol Bae; Yoon-Kyoung Sung
Journal:  J Korean Med Sci       Date:  2014-05-30       Impact factor: 2.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.